Adenovirus-interleukin-12-mediated tumor regression in a murine hepatocellular carcinoma model is not dependent on CD1-restricted natural killer T cells

Cancer Research

Volumn 60, Issue 22, 2000, Pages 6457-6464

  Andrews, Kahlil J ^a   Ribas, Antoni ^a   Butterfield, Lisa H ^a   Vollmer, Charles M ^a   Eilber, Fritz C ^a   Dissette, Vivian B ^a   Nelson, Scott D ^a   Shintaku, Peter ^a   Mekhoubad, Shahram ^a   Nakayama, Toshinori ^b   Taniguchi, Masaru ^b   Glaspy, John A ^a   McBride, William H ^a   Economou, James S ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b CHIBA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 8; CD1 ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; INTERLEUKIN 12;

ADENOVIRUS; ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL MEDIATED CYTOTOXICITY; CONTROLLED STUDY; LIVER CELL CARCINOMA; MOUSE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE SUBPOPULATION; TUMOR REGRESSION; TUMOR VASCULARIZATION;

ADENOVIRIDAE; ANIMALS; ANTIGENS, CD1; ANTIGENS, CD28; CYTOTOXICITY, IMMUNOLOGIC; DISEASE MODELS, ANIMAL; HUMANS; IMMUNOCOMPROMISED HOST; INTERLEUKIN-12; KILLER CELLS, NATURAL; LIVER NEOPLASMS, EXPERIMENTAL; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MICE, SCID; NEOVASCULARIZATION, PATHOLOGIC; PORE FORMING CYTOTOXIC PROTEINS; T-LYMPHOCYTES;

EID: 0033692861     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (52)

1. Identification and purification of natural killer cell stimulatory factor (NKSF), a cytokine with multiple biologic effects on human lymphocytes
2. Purification to homogeneity and partial characterization of cytotoxic lymphocyte maturation factor from human B-lymphoblastoid cells
3. IL-12 induces T helper 1-directed antitumor response
4. Interleukin-12: Potential role in cancer therapy
5. Immunobiology of interleukin-12
6. Role of interferon-γ in mediating the antitumor efficacy of interleukin-12
7. Immune events associated with the cure of established tumors and spontaneous metastases by local and systemic interleukin 12
8. IL-12 regulates VEGF and MMPs in a murine breast cancer model
9. Multiple molecular and cellular changes associated with tumour stasis and regression during IL-12 therapy of a murine breast cancer model
10. Antitumor activity of interleukin 12 in preclinical models
11. The potential of interleukin-12 for use in cancer therapy
12. Hypoxia-mediated apoptosis from angiogenesis inhibition underlies tumor control by recombinant interleukin 12
13. Recombinant IL-12 administration induces tumor regression in association with IFN-γ production
14. Antitumor efficacy of adenocarcinoma cells engineered to produce interleukin 12 (IL-12) or other cytokines compared with exogenous IL-12
15. Antitumor effects of interleukin-12 in pre-clinical and early clinical studies
16. Eradication of murine bladder carcinoma by intratumor injection of a bicistronic adenoviral vector carrying cDNAs for the IL-12 heterodimer and its inhibition by the IL-12 p40 subunit homodimer
17. Interleukin-12: Murine models of a potent antitumor agent
18. Presentation of peptide antigens by mouse CD1 requires endosomal localization and protein antigen processing
19. Mouse CD1-specific NK1 T cells: Development, specificity, and function
20. Highly conserved antigen-presenting function of CD1d molecules
21. Rapid death and regeneration of NKT cells in anti-CD3ε- or IL-12-treated mice: A major role for bone marrow in NKT cell homeostasis
22. Selective ability of mouse CD1 to present glycolipids: α-galactosylceramide specifically stimulates Vα14+ NK T lymphocytes
23. CD1d-restricted and TCR-mediated activation of vα14 NKT cells by glycosylceramides
24. Natural killer-like nonspecific tumor cell lysis mediated by specific ligand-activated Vα14 NKT cells
25. Requirement for Vα14 NKT cells in IL-12-mediated rejection of tumors
26. Critical role of NK1+ T cells in IL-12-induced immune responses in vivo
27. Cytokine gene therapy for human tumors
28. A comparison of gene transfer methods in human dendritic cells
29. Construction of a double recombinant adenovirus vector expressing a heterodimeric cytokine: In vitro and in vivo production of biologically active interleukin-12
30. Transduction of routine and human tumors using recombinant adenovirus vectors
31. Expression of liver phenotypes in cultured mouse hepatoma cells
32. Biological behavior of malignant melanoma cells correlated to their survival in vivo
33. In vivo therapy of hepatocellular carcinoma with a tumor-specific adenoviral vector expressing interleukin-2
34. Mechanisms of lymphocyte-mediated lysis
35. The role of B7 costimulation in T-cell immunity
36. Direct intratumoral injection of an adenovirus expressing interleukin-12 induces regression and long-lasting immunity that is associated with highly localized expression of interleukin-12
37. Adenovirus-mediated interleukin-12 gene therapy for metastatic colon carcinoma
38. Regression of colon cancer and induction of antitumor immunity by intratumoral injection of adenovirus expressing interleukin-12
39. Adenovirus-mediated interleukin-12 gene therapy for prostate cancer: Suppression of orthotopic tumor growth and pre-established lung metastases in an orthotopic model
40. Essential requirement of an invariant Vα14 T cell antigen receptor expression in the development of natural killer T cells
41. Concanamycin A, a powerful tool for characterization and estimation of contribution of perfofin- and Fas-based lyric pathways in cell-mediated cytotoxicity
42. Antigen-presenting function of mouse CD1: One molecule with two different kinds of antigenic ligands
43. The CD1 family of lipid antigen-presenting molecules
44. Fighting cancer by attacking its blood supply
45. The prognostic significance of angiogenesis in epithelial ovarian carcinoma
46. Relationship of endothelial cell proliferation to tumor vascularity in human breast cancer
47. Spectrum of tumor angiogenesis in the bone marrow of children with acute lymphoblastic leukemia
48. Tumor angiogenesis and metastasis: Correlation in invasive breast carcinoma
49. Inhibition of angiogenesis in vivo by interleukin 12
50. Inhibition of angiogenesis by interleukin-12 is mediated by the interferon-inducible protein 10
51. Human interferon-inducible protein 10 is a potent inhibitor of angiogenesis in vivo
52. Insights into MMP-TIMP interactions